HEP 689Alternative Names: SB 235699
Latest Information Update: 03 Nov 2000
At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Imidazoles; Small molecules
- Mechanism of Action Cytokine inhibitors; Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis